Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianda PharmaceuticalsHKSE:00455 -12.60%24 Days Payable is 136.48 as of Dec. 2025, which is 1% above its 10-year median of 135.25. GuruFocus rates HKSE:00455 with a GF Score™ of 24/100 and a GF Value™ of HK$0.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Tianda Pharmaceuticals ranks better than 76.06% on this metric.
The historical rank and industry rank for Tianda Pharmaceuticals's Days Payable or its related term are showing as below:
HKSE:00455'
s Days Payable Range Over the Past 10 Years
Min: 56.95 Med: 135.25 Max: 328.9
Current: 151.65
During the past 13 years, Tianda Pharmaceuticals's highest Days Payable was 328.90. The lowest was 56.95. And the median was 135.25.
HKSE:00455's Days Payable is ranked better than 76.06% of 923
companies
in the Drug Manufacturers industry
Industry Median: 88.47
vs HKSE:00455: 151.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianda Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Tianda Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tianda Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianda Pharmaceuticals (HKSE:00455) has a Days Payable of 136.48 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tianda Pharmaceuticals and its competitors. This is near median its historical median of 135.25. Over the past decade, Tianda Pharmaceuticals' Days Payable has ranged from 56.95 to 328.90. According to the industry distribution chart, Tianda Pharmaceuticals ranks #221 out of 923 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Tianda Pharmaceuticals' Days Payable too high?
Tianda Pharmaceuticals' current Days Payable of 136.48 is near median its 10-year median of 135.25. Over the past 10 years, this metric has ranged from a low of 56.95 to a high of 328.90. The Drug Manufacturers industry median Days Payable is 88.47. Tianda Pharmaceuticals' value of 136.48 is 54.3% above this industry median. Based on the distribution chart, Tianda Pharmaceuticals ranks #221 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tianda Pharmaceuticals has a GF Score™ of 24/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tianda Pharmaceuticals' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianda Pharmaceuticals ranks #221 out of 923 companies for Days Payable. This places Tianda Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Days Payable is 88.47. Tianda Pharmaceuticals' value of 136.48 is 54.3% above this benchmark. Historically, Tianda Pharmaceuticals' own Days Payable has ranged from 56.95 to 328.90 over the past decade. While the company's 10-year median is 135.25 vs. the industry median of 88.47, Tianda Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.47, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianda Pharmaceuticals's current Days Payable of 136.48 is 54.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tianda Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianda Pharmaceuticals's current Days Payable is 136.48, which is near median its own 10-year median of 135.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tianda Pharmaceuticals (HKSE:00455) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.11 — trading 14.6% below its estimated fair value. The current Days Payable is 136.48, which is near median its 10-year median of 135.25 and 54.3% above the Drug Manufacturers industry median of 88.47. Tianda Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tianda Pharmaceuticals (HKSE:00455), the current Days Payable is 136.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?
Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued.
The current stock price of HK$0.11 is trading 14.6% below its estimated GF Value™ of HK$0.13.
GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKSE:00455:
Days Payable: 136.48 (near median its 10-year median of 135.25)
GF Value™: HK$0.13 vs. price of HK$0.11 (14.6% below fair value)
Industry Position: 54.3% above the Drug Manufacturers median (#221 of 923)
No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
24GF Score
Get the complete analysis for HKSE:00455
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00455 has been successfully added to your 
